ID: ALA4168274

Max Phase: Preclinical

Molecular Formula: C24H27N3O3

Molecular Weight: 405.50

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  NC(=O)c1ccc(-n2cccc2Cc2ccccc2O)cc1N[C@H]1CC[C@H](O)CC1

Standard InChI:  InChI=1S/C24H27N3O3/c25-24(30)21-12-9-19(15-22(21)26-17-7-10-20(28)11-8-17)27-13-3-5-18(27)14-16-4-1-2-6-23(16)29/h1-6,9,12-13,15,17,20,26,28-29H,7-8,10-11,14H2,(H2,25,30)/t17-,20-

Standard InChI Key:  DAFDTRSWRWXFIR-IRJFHVNHSA-N

Associated Targets(Human)

Heat shock protein HSP 90-alpha 4115 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Endoplasmin 514 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Heat shock protein 90 beta 139 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 405.50Molecular Weight (Monoisotopic): 405.2052AlogP: 3.59#Rotatable Bonds: 6
Polar Surface Area: 100.51Molecular Species: NEUTRALHBA: 5HBD: 4
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 5#RO5 Violations (Lipinski): 0
CX Acidic pKa: 10.01CX Basic pKa: 3.06CX LogP: 3.87CX LogD: 3.87
Aromatic Rings: 3Heavy Atoms: 30QED Weighted: 0.50Np Likeness Score: -0.72

References

1. Jiang F, Guo AP, Xu JC, You QD, Xu XL..  (2018)  Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis.,  61  (21): [PMID:30351001] [10.1021/acs.jmedchem.8b00800]
2. Li L, Wang L, You QD, Xu XL..  (2020)  Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.,  63  (5): [PMID:31663736] [10.1021/acs.jmedchem.9b00940]
3. Yu J, Zhang C, Song C..  (2022)  Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances.,  238  [PMID:35691175] [10.1016/j.ejmech.2022.114516]

Source